Overview
- Cipla reported on July 23, 2026 that consolidated net profit fell about 39% to roughly ₹789 crore while revenue rose about 2.3% to ₹7,119.28 crore.
- Management blamed the profit decline mainly on steep price erosion in North American oncology generics after loss of exclusivity, notably for the Revlimid generic.
- U.S. sales were also weakened after a U.S. FDA inspection at the plant of Cipla’s sole lanreotide supplier led to a temporary production halt and reduced shipments of the tumor therapy.
- To steady results the company is shifting emphasis to India chronic therapies and the licensed GLP‑1 obesity drug Yurpeak, which held about a 15.7% market share in June, and it highlighted VAI classification for its Goa site as a regulatory positive for future complex filings.
- The results missed analyst estimates, the stock fell about 2% on the day, and management signaled hopes for margin recovery from pipeline launches and stronger second‑half execution.